A combined target-based and ligand-based drug design approach has been carried out to define a novel pharmacophore model of the human A3 receptor antagonists. High throughput molecular docking and comparative molecular field analysis (CoMFA) have been used in tandem to assemble a new target based pharmacophore model.

Combined Target-based and Ligand-based Drug Design Approach as Tool to Define a Novel Pharmacophore Model of Human A3 Adenosine Receptor Antagonists: Pyrazolo[4,3-E]1,2,4-Triazolo[1,5-C]Pyrimidine Derivatives as a Key Study

SPALLUTO, GIAMPIERO
2005-01-01

Abstract

A combined target-based and ligand-based drug design approach has been carried out to define a novel pharmacophore model of the human A3 receptor antagonists. High throughput molecular docking and comparative molecular field analysis (CoMFA) have been used in tandem to assemble a new target based pharmacophore model.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11368/1689375
 Avviso

Registrazione in corso di verifica.
La registrazione di questo prodotto non è ancora stata validata in ArTS.

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 74
  • ???jsp.display-item.citation.isi??? ND
social impact